SWOG clinical trial number
SWOG-9458
Evaluation of Ki-67, p53 and Angiogenesis in Patients Registered to SWOG-8710, Ancillary
Closed
Phase
Accrual
58%
Published
Abbreviated Title
Ancillary
Activated
11/15/1995
Closed
11/01/1998
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2006
Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group study
2002
SWOG 9458: evaluation of Ki-67, p53 and angiogenesis in patients registered to SWOG 8710
Other Clinical Trials
SWOG Clinical Trial Number
S2427
Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26
A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase